Dementia Mental and Behavioural Disorders
Conditions
Interventions
Clusters will be randomized at GP level into an intervention group (tablet-based intervention) and a control group (treatment as usual plus information handbook). After randomization, in both groups,
Sponsors
Charité - Universitätsmedizin Berlin
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current participant inclusion criteria as of 05/04/2022: GPs: 1. Operates as a GP 2. Practice meets technical requirements (wifi connection available or can be installed) 3. Willing to participate in training 4. Signed cooperation agreement/informed consent to participate in the study PwD: 5. Diagnosis of dementia: ICD-10 F00-F03, G30, G31.0 and G31.82 6. Living at home and receiving outpatient care or living in dementia shared homes (Demenz WG) 7. Signed informed consent to participate in the study (possibly through legal advisors) Informal caregiver: 8. Signed informed consent to participate in the study Previous participant inclusion criteria: GPs: 1. Operates as a GP 2. Practice meets technical requirements (wifi connection available or can be installed) 3. Willing to participate in training 4. Signed cooperation agreement/informed consent to participate in the study PwD: 5. Diagnosis of dementia: ICD-10 F00-F03, G30, G31.0 and G31.82 6. Living at home and receiving outpatient care 7. Informal caregiver available 8. Signed informed consent to participate in the study (possibly through legal advisors) Informal caregiver: 9. Living with or regularly visiting PwD 10. Signed informed consent to participate in the study
Exclusion criteria
Exclusion criteria: GPs: 1. planned absence or closing of the practice longer than four weeks during the study period PwD: 2. Other mental and behavioral disorders: ICD-10 Diagnosis F10-29 (except F10.1, F10.1, F17.1 or F17.2), F32.2 and F32.3 3. Planned hospital or rehabilitation stay longer than 4 weeks 4. Planned relocation to an inpatient care-facility or nursing home within the study period Informal caregiver: 5. Planned absence longer than 8 weeks during the study period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Guideline adherence assessed using a checklist at baseline and at 9 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 05/04/2022: Secondary outcomes at PwD level measured at baseline and at 9 months: 1. Dementia-related quality of life measured using the QOL-AD questionnaire 2. Health status measured using the EQ-5D-5L measure 3. Behavioural symptoms measured using the Neuropsychiatric Inventory (NPI-PH) 4. Functional independence assessed using the Barthel Index for Activities of Daily Living (ADL) 5. Dementia stage assessed using the Functional Assessment Staging Test (FAST) 6. Depression measured using the Depression in Old Age Scale (DIA-S) 7. Medication intake assessed using lists obtained from the GP as well as from the PwD and caregiver Secondary outcomes at informal caregiver level measured at baseline and at 9 months: 1. Depression measured using the Geriatric Depression Scale (GDS) 2. Caregiver burden measured using the Burden Scale for Family Caregivers (BSFC) 3. Health status measured using the Short Form (36) Health Survey (SF-36) Secondary outcome for all participants (GPs, PwD, caregivers) measured at 9 months: 1. Evaluation of the tablet-based application using the Technikaffinitaet – Elektronische Geraete (TA-EG, Technology Affinity – Electronic Devices) questionnaire, Usability Scale and AttrakDiff mini questionnaire as well as a set of self-developed items Previous secondary outcome measures: Secondary outcomes at PwD level measured at baseline and at 9 months: 1. Dementia-related quality of life measured using the QOL-AD questionnaire 2. Health status measured using the EQ-5D-5L measure 3. Behavioural symptoms measured using the Neuropsychiatric Inventory (NPI-PH) 4. Cognition measured using the Mini-Mental State Examination (MMSE) 5. Functional independence assessed using the Barthel Index for Activities of Daily Living (ADL) 6. Dementia stage assessed using the Functional Assessment Staging Test (FAST) 7. Depression measured using the Depression in Old Age Scale (DIA-S) 8. Medication intake assessed using lists o | — |
Countries
Germany
Contacts
Public ContactSonia Lech
Outcome results
None listed